譜尼測試(300887.SZ):今年CRO/CDMO業務整個配套的供應鏈條齊全了,業務的協同性在持續加強
格隆匯5月12日丨譜尼測試(300887.SZ)於2023年4月20日-5月11日接受現場參觀、參加路演活動或召開電話會議、業績説明會,問答環節中,就“CRO/CDMO板塊今年的一季度業績較快,具體的原因主要有哪些?這個板塊全年目標如何?”,公司回覆稱,今年我們CRO/CDMO業務整個配套的供應鏈條齊全了,業務的協同性在持續加強。公司內部具有非常強勁的技術氛圍,集團董事長宋總的技術背景,還有我們的獨董也是在這方面的專家,公司一季度成功併購湖北中佳製藥合成股份有限公司,具備了原料藥GMP生產體系和生產能力,打通生物醫藥一站式技術平台“最後一公里”。因此可以説CRO/CDMO板塊,我們對此投入了很多資金和精力,包括上海實驗室動物毒理實驗室全面投入使用,吸引了大量的CRO的研發人員,包括研發費用的增長和研發人員的增加,與重要的一些客户保持密切業務聯繫等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.